tbuckley/cabot-search huggingface dataset:
Domiciliary Visiting
Authors: J. Gottlieb
Journal: BMJ (1967)

Treatment of ovariectomized rats with dietary clofibrate caused a manyfold increase in the liver microsomal esterification of estradiol with fatty acids. The stimulatory effect of clofibrate administration on fatty acid esterification of estradiol by liver microsomes was paralleled in vivo by enhanced estradiol-induced increases in the formation of lobules in the mammary gland and by increased incorporation of bromodeoxyuridine into these lobules. In contrast to the stimulatory effect of clofibrate administration on the action of estradiol in the mammary gland, clofibrate administration had no effect on the uterotropic action of estradiol. These results indicate that clofibrate administration has a selective stimulatory effect on the hormonal action of estradiol in the mammary gland but not in the uterus.
Abstract 63: Hands-On Defibrillation: An Analysis of Current Flow Through Rescuers In Contact With Patients During Biphasic External Defibrillation
Authors: Michael S Lloyd, Eric L Krivitsky, Paul F Walter, Jonathan J Langberg
Journal: Circulation (2007)

Background: During cardiopulmonary resuscitation, the need for rescuers to stand clear before a shock is delivered invariably interrupts chest compressions. Brief interruptions like these reduce the efficacy of defibrillation in animal models. Current flow through a rescuer in contact with a patient being shocked with modern biphasic waveforms and adhesive patch electrodes has not been investigated. We hypothesized that leakage current is low through a rescuer performing chest compressions at the time of shock delivery. Methods: During 18 elective cardioversions using truncated exponential biphasic waveforms (median energy 200 joules, range 100 –360 joules), an investigator serving as the rescuer placed a gloved hand on the patient’s anterior chest immediately adjacent to the defibrillating patch with approximately 20lbs of pressure to simulate chest compressions. Skin electrodes were used to connect the rescuer’s thigh to the patient’s posterior shoulder, simulating a worst-case return current pathway. During shock delivery, voltage and current through the rescuer (hand to thigh) were recorded using a digital storage oscilloscope during the shock delivery. Results: In no cases were shocks perceptible to the rescuer. Mean patient transthoracic impedance was 57 +/− 14 ohms (range 36 –79 ohms). Potential differences in volts (V) between the rescuer’s wrist and thigh ranged from 1.7 to 14 V (mean 6.7 +/− 2.7 V). Calculated impedances through rescuers ranged from 8,190 to 100,400 ohms (mean 30,100 +/− 20,400 ohms). The average leakage current flowing through the rescuer’s body for each phase of the shock waveform was 273 +/−191 microamperes (range 1 to 910 microamperes). All measured values in our series were well below 2,500 microamperes, an accepted safety standard for earth-leakage current in medical devices. Conclusions: Even in a simulated worst-case scenario, a rescuer performing chest compressions during biphasic external defibrillation is exposed to low levels of leakage current. Our findings demonstrate the safety and feasibility of uninterrupted chest compressions during shock delivery, which may enhance the efficacy of defibrillation and cardiocerebral perfusion.
Pembrolizumab in gastrointestinal (GI) malignancies with defective DNA mismatch repair (dMMR): A single institution experience.
Authors: Courtney Christine Cavalieri
Journal: Journal of Clinical Oncology (2017)

e23081 Background: Defective DNA mismatch repair is associated with increased mutation load and expression of neoantigens. Increased activity of PD-1 inhibitor is reported in patients with GI cancers with dMMR. Here, we describe our experience at Huntsman Cancer Institute with PD-1 inhibition in subjects with GI malignancies with dMMR. Methods: Retrospective chart review of patients with metastatic GI malignancies with dMMR, treated with pembrolizumab at Huntsman Cancer Institute between July 15, 2015 and February 6, 2017. Results: A total of 9 patients were identified that received at least 1 dose of pembrolizumab [colorectal (CRC) n = 4; extrahepatic cholangiocarcinoma (EHCC) n = 2; pancreatic adenocarcinoma (PDAC) n = 2; adenocarcinoma of the appendix n = 1]. Five patients received concurrent cytoxic chemotherapy at some point in treatment. Median number of doses given: 6.5 (3-18). Median age: 61 years (33-73 years). Eight patients were evaluable for response per RECIST. Two patients had complete responses (EHCC and CRC). Two patients had a partial response: PDAC (-57%, time to progression [TTP] +11 months) and CRC (-38%, TTP +6 months). Three patients had stable disease: PDAC (-28%, TTP +5 months), CRC (-6%), and adenocarcinoma of the appendix. One patient with CRC died from upper GI bleeding. Two patients experienced toxicities requiring discontinuation of pembrolizumab. The first patient experienced grade 3 hyperthyroidism and adrenal insufficiency. The second patient had an incidental finding of pneumonitis and enlarged mediastinal lymph nodes on restaging CT scan, biopsy showed non-necrotizing granulomas consistent with sarcoidosis. One patient had grade 2 pneumonitis that was treated and resolved on steroids. This patient continues on pembrolizumab. Conclusions: Single-institution data seem to confirm activity of PD-1 inhibitor in GI malignancies that harbor dMMR. At time of abstract submission, six patients remain on single agent pembrolizumab. Complete responses were seen in CRC and EHCC. Two patients (PDAC and CRC) attained a partial response. Updated responses for all patients will be presented during the meeting.
Treatment of progressive metastatic glomus jugulare tumor (paraganglioma) with gemcitabine
Authors: J. Marc Pipas, Robert F. Krywicki
Journal: Neuro-Oncology (2000)

Paragangliomas are rare tumors of the paraganglia composed of specialized neural crest cells arising in association with sympathetic ganglia.Here we report a case of progressive, metastatic paraganglioma (glomus jugulare tumor) responsive to single agent gemcitabine.In addition, a brief review of chemotherapy for paraganglioma follows the case presentation.
Cottage Hospitals
Authors: H. C. Burdett
Journal: BMJ (1882)

<h3>Abstract</h3> Respiratory viruses are highly infectious; however, the variation of individuals’ physiologic responses to viral exposure is poorly understood. Most studies examining molecular predictors of response focus on late stage predictors, typically near the time of peak symptoms. To determine whether pre- or early post-exposure factors could predict response, we conducted a community-based analysis to identify predictors of resilience or susceptibility to several respiratory viruses (H1N1, H3N2, Rhinovirus, and RSV) using peripheral blood gene expression profiles collected from healthy subjects prior to viral exposure, as well as up to 24 hours following exposure. This analysis revealed that it is possible to construct models predictive of symptoms using profiles even prior to viral exposure. Analysis of predictive gene features revealed little overlap among models; however, in aggregate, these genes were enriched for common pathways. Heme Metabolism, the most significantly enriched pathway, was associated with higher risk of developing symptoms following viral exposure.
DNA probes. Fruits of the new biotechnology
Authors: F. E. Young
Journal: JAMA (1987)

The emergence of recombinant DNA technology in the 1970sgiven rise to new diagnostic techniques based on DNA probes. The Food and Drug Administratitration'shese probes stems from its regulatory responsibilities regarding DNA probes as medical devices. The agency also sees DNA probes as valuable tools in meeting its mission of identifying, preventing, and resolving public health problems, especially in the area of food safety. The development of DNA probes for genetic diseases is raising medical and ethical questions that must be addressed by the medical community, whose ultimate responsibility must be to see that this new technology is used wisely, appropriately, and correctly. (<i>JAMA</i>1987;258:2404-2406)
SUITS FOR DAMAGES AGAINST PHYSICIANS.
Journal: JAMA (1900)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Reply
Authors: N P J Cripps, R J Heald
Journal: Gut (1996)

not imposed.3Thomas and colleagues report a significantly higher rate of screen com- pliance among participants living with other participants, while those who had a diagnostic colorectal examination with negative results had significantly lower odds of complying.4Another study showed that compliance in first degree relatives ofpatients with colorectal cancer was significantly higher than in spouses (69% versus 47%, p<0-01), as was among those whose relatives died recently from col- orectal cancer.5However they found that time since diagnosis in the index case had no effect on the compliance rate, in contrast with the findings by the authors.Finally, Neilson and coworker report that compliers are found to be of higher socioeconomic classes than per- sistent non-compliers, to have more personal and family experience of illness, and to visit their dentists more regularly.6These data, in conjunction with that presented by the authors, helps us better under- stand the factors affecting compliance, while screening for colorectal cancer.
Hepatitis B transmission in a family
Authors: W. E. Mitch
Journal: JAMA (1974)

An epidemic of hepatitis B antigen (HB Ag)-positive viral hepatitis occurred in a large family and their acquaintances during a four-month period. Three adult members of the family had clinically apparent hepatitis and asymptomatic HB Ag-positive serum developed in the baby and grandmother. Two other family members were found to have antibody to hepatitis B. No one in the family but the index patient used illicit drugs parenterally but all had close contact with the index patient, the baby, and each other. This outbreak suggests means by which HB Ag may be transmitted by nonparenteral or inapparent parenteral routes in a family setting.
No Physician Can Shun Role In Political Life
Journal: JAMA (1960)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Other
Authors: Eric Roehm
Journal: JAMA (1985)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Drug allergy
Authors: N. F. Adkinson
Journal: JAMA (1992)

<h3>CASE PRESENTATION</h3> The patient was a 67-year-old woman admitted with polyuria, dysuria, and fever. Her medical history was unremarkable, she was taking no medications, and had no known drug allergies. Her family history, social history, and review of systems were noncontributory. On physical examination, the patient was mildly obese and her blood pressure was 184/100 mm Hg. She was afebrile at the time of admission. The rest of her examination was unremarkable. Routine laboratory tests showed hyperglycemia and glycosuria, and the diagnosis of diabetes mellitus was made. Microscopic examination of the urine showed many white blood cells and many bacteria, and subsequently<i>Escherichia coli</i>was grown from a urine culture. The patient was given a combination of trimethoprim and sulfamethoxazole for her urinary tract infection, but could not tolerate it because of nausea and vomiting. Enalapril was prescribed for hypertension, and glyburide for the diabetes (Table 1). On the second
The false-negative Treponema pallidum immobilization test in syphilis. Pseudobiologic false-positive syndrome
Authors: J. L. Smith
Journal: JAMA (1967)

THE<i>Treponema pallidum</i>immobilization test has achieved worldwide recognition as a specific serological test for syphilis since its introduction by Nelson and Mayer in 1949. It has been particularly helpful to clinicians in two sets of circumstances: detecting late cases of seronegative syphilis and evaluating the biologic false-positive reactor. The latter (or the occurrence of a reactive serum reagin test in a patient not previously infected with<i>T pallidum</i>, but suffering from another entity, such as a collagen vascular disease) is a well-recognized phenomenon. The finding of a weakly reactive serum venereal disease research laboratory (VDRL) test in a patient on routine testing, but in whom on subsequent study a nonreactive TPI test is found, has come to be the serologic hallmark of the biologic false-positive reactor. However, false-negative TPI tests do occur. The development of a new specific blood test for syphilis, the fluorescent treponemal antibody absorbed (FTA-ABS) test,
Six-month compliance after hospital discharge in patients with acute coronary syndromes Akhil Gulati, Eva M. Kline-Rogers, Obli C. M. Mani, Deepak Venkat, Jeanna V. Cooper, Gwen E. Kearly, Elizabeth Nolan, Robert J. Cody, Steven R. Erickson, Rajendra H. Mehta, Kim A. Eagle, The University of Michigan Heart Care Program. University of Michigan Health Systems, Ann Arbor, MI
Journal: Journal of the American College of Cardiology (2001)
Progesterone Drug May Reduce Benign Prostatic Hypertrophy
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Risk of Prenatal Opioid Prescribing
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Phase I trial of metronomic cyclophosphamide (CTX), bevacizumab (BV) and imatinib (IM) in patients (pts) with advanced solid tumors
Authors: E. K. Bergsland, A. H. Ko, M. A. Tempero, K. Whittaker, T. Weber, L. Fong, J. W. Park, D. Hanahan, A. P. Venook
Journal: Journal of Clinical Oncology (2008)

15026 Background: Low-dose chemotherapy without scheduled breaks (metronomic chemotherapy) is thought to be anti-angiogenic. Inhibitors of the VEGF and the PDGF signaling pathways may augment this effect. We initiated a prospective, phase I pharmacokinetic (PK) and biomarker study to assess the safety of a rationally designed combination anti-angiogenesis strategy consisting of metronomic CTX, BV (an anti-VEGF antibody), and IM (a PDGF-receptor inhibitor). Methods: Cycle length was 28 days. Doses: BV 5 mg/kg IV q 14 d, CTX 25–50 mg PO QD, IM 400–800 mg PO QD. DLT was defined as any treatment-related grade 4 hematologic event or grade 3/4 non-hematologic event during cycles 1 and 2. Quantification of circulating tumor cells (CTC), endothelial cells (CEC, aEC) and endothelial progenitor cells (EPC) was performed. Treatment-related effects on parameters measured by CT perfusion were assessed. Results: 10 pts with metastatic colorectal cancer have been enrolled: M/ F= 5/5; ECOG PS 0/1= 9/1; median age=55 (range 33–63). All pts had received prior BV and had disease refractory to standard chemotherapy (oxaliplatin, irinotecan, and a fluoropyrimidine). Pts have received treatment for a median of 56 days (range 21–222 days). Dose level 0 (DL 0) (BV 5 mg/kg, CTX 25 mg/d, IM 400 mg/d) was expanded to 6 pts after 1/3 initial pts was removed from the study for a Gr 2 gastrointestinal fistula (after cycle 1). DL+1 (BV 5 mg/kg, CTX 50 mg/d, IM 400 mg/d) had no DLT’s. 1 pt has been enrolled on DL+2 (BV 5 mg/kg, CTX 50 mg/d, I 300 mg/BID). The MTD has not been reached. Treatment has been well tolerated; there have been no treatment-related Gr 3/4 toxicities. The most common possible treatment-related AE’s have been Gr 1/2 fatigue, lymphopenia, nausea, and rash. Two pts (DL 0, DL+1) demonstrated SD lasting > 6 months; 1 of whom had a 19% decrease in target lesions by RECIST. Conclusions: The combination of metronomic CTX, IM, and BV can be safely administered. Class related side effects have been seen. Preliminary clinical activity has been observed in a heavily-pretreated patient population. Enrollment to this study continues, with CTX and IM PK to be performed at the MTD. Updated clinical and biomarker data will be presented. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Genentech™ BioOncology, Johnson & Johnson, sanofi-aventis Genentech™ BioOncology, Johnson & Johnson, Novartis
Progress in Cardiology
Authors: David H. Spodick
Journal: JAMA (1972)

In the first number of a new series, summarizing significant advances in cardiology, the distinguished editors have assembled contributions by 19 outstanding British and American investigators. Each of 10 chapters is a self-contained unit, and most of them successfully cover all important aspects of their subjects in surprising depth, considering the average length of 27 pages. Indeed, for excellence of presentation it is difficult to choose among them. Blackburn's "Computers in Cardiology" is a lucid introduction to analogue and digital theory and practice. Dollery and colleagues ably present the "hot" but as yet insufficiently penetrated topic of drug interactions. "The Genesis of Cardiac Arrhythmias in Acute Myocardial Infarction," by Jewitt, is a thorough and statistically documented paper with a completely up-to-date discussion of mechanisms, including appropriate caveats for the superficially attractive but unproved arrhythmogenic role of atrial pericarditis. This is complemented by Yatteau and Wallace's superb treatise on the clinical
Cirrhotic extracellular matrix affects Hic-5 expression in primary human hepatic stellate cells
Authors: Simona Onali, Elisabetta Caon, Kessarin Thanapirom, Martina Marrali, Maria Giovanna Vilia, Luca Frenguelli, Walid Al-Akkad, Giuseppe Mazza, Massimo Pinzani, Krista Rombouts
Journal: Journal of Hepatology (2020)